Should You Buy Johnson & Johnson Stock Before Its Big Coronavirus Vaccine News?
The biggest healthcare company in the world has some really big news on the way. Johnson & Johnson (NYSE: JNJ) should announce results from a late-stage study of its COVID-19 vaccine candidate, JNJ-78436735, any day now.
What makes J&J's results so highly anticipated is that its vaccine requires only a single dose instead of two doses as coronavirus vaccines already on the market require. This could give J&J a significant competitive advantage over its rivals.
With a potentially momentous announcement imminent, should you buy Johnson & Johnson stock before the big news hits? The answer is a little complicated.
Source Fool.com
